Flies are a widely distributed pest insect that poses a significant threat to food security. Flight is essential for the dispersal of the adult flies to find new food sources and ideal breeding spots. The supply of metabolic fuel to power the flight muscles of insects is regulated by adipokinetic hormones (AKHs). The fruit fly, Drosophila melanogaster, the flesh fly, Sarcophaga crassipalpis, and the oriental fruit fly, Bactrocera dorsalis all have the same AKH that is present in the blowfly, Phormia terraenovae; this AKH has the code-name Phote-HrTH. Binding of the AKH to the extracellular binding site of a G protein-coupled receptor causes its activation. In this thesis, the structure of Phote-HrTH in SDS micelle solution was determined using NMR restrained molecular dynamics. The peptide was found to bind to the micelle and be reasonably rigid, with an S 2 order parameter of 0.96. The translated protein sequence of the AKH receptor from the fruit fly, Drosophila melanogaster, the flesh fly, Sarcophaga crassipalpis, and the oriental fruit fly, Bactrocera dorsalis were used to construct two models for each receptor: Drome-AKHR, Sarcr-AKHR, and Bacdo-AKHR. It is proposed that these two models represent the active and inactive state of the receptor. The models based on the crystal structure of the β-2 adrenergic receptor were found to bind Phote-HrTH with a predicted binding free energy of –107 kJ mol–1 for Drome-AKHR, –102 kJ mol–1 for Sarcr-AKHR and –102 kJ mol–1 for Bacdo-AKHR. Under molecular dynamics simulation, in a POPC membrane, the β-2AR receptor-like complexes transformed to rhodopsin-like. The identification and characterisation of the ligand-binding site of each receptor provide novel information on ligand-receptor interactions, which could lead to the development of species-specific control substances to use discriminately against these pest flies.

<p> Obesity is a growing concern as 42.3% of people in the U.S were considered obese in the years 2017- 2018. Little is known about the genetic components that contribute to weight gain. In humans, the hormone glucagon is a major contributor to the body’s energy demand as it helps break down lipids. Therefore, learning more about this pathway could enable a range of therapeutics. In fact, studies have shown that glucagon treatments have helped patients with both weight loss and appetite suppression. In this project, we analyzed candidate genes that modify the glucagon pathway in <em>Drosophila melanogaster.</em> We reduced the expression of the fly version of the glucagon receptor (AKHR) in our model. This induces fat retention in the L3 larvae, which mimics obesity in humans. We then crossed our model to the DGRP and looked for natural variation in fat content using a density assay. The density assay examines the relative fat levels of the larvae by slowly increasing the amount of sucrose in water. This enables us to observe whether we have lean larvae which float later or fat larvae which float early on. We used the variation in floating concentration to identify candidate modifier genes through GWA or genome-wide association study. We crossed our <em>AKHR</em> RNAi model to RNAi for various candidate modifier genes that may enhance or suppress fat retention. We screened these candidates initially with the same density assay used in the original study. This resulted in four candidate genes that significantly impacted the density of the larvae: <em>THADA</em>, <em>AmyD</em>, <em>GluRIIC</em>, and <em>CG9826</em>. We further characterized these candidates using biochemical assays to analyze stored metabolites such as triglycerides, glucose, glycogen, and protein. These have been further analyzed under control, high sugar, and high fat conditions to see if the larvae are resistant to environmental changes. <em>CG9826</em> showed significant increase in stored fats across all environments. <em>THADA</em> RNAi showed an increase in fat in the high fat environment. Overexpression of <em>THADA</em> showed a decrease in fat storage in the high fat environment. Our goal is to advance our understanding of the glucagon signaling pathway, obesity, and lipid metabolism. We are also hopeful to provide candidate genes that can be regarded as future therapeutic targets. </p>